Your session is about to expire
← Back to Search
Paclitaxel + Trastuzumab +/- Lapatinib for Breast Cancer
Study Summary
This trial is testing paclitaxel with trastuzumab with or without lapatinib to see how well they work in treating patients with stage II or stage III breast cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My cancer is at stage III and has been checked for spread.My tumor is HER2 positive, confirmed by specific tests.I haven't received any treatment for this cancer.I have been diagnosed with invasive breast cancer, not inflammatory breast cancer.I am a woman not pregnant, post-hysterectomy, menopausal, or haven't had a period for 24 months.I know my cancer's estrogen and progesterone receptor status.Your heart's pumping function must be at least 50% as measured by certain tests.Your bilirubin level is not more than 1.5 times the upper limit of normal.I am fully active or can carry out light work.Your AST and ALT levels are not more than 2.5 times the normal limit.I have cancer in more than one location, but it meets the study's criteria.I have stage II-III breast cancer and plan to have surgery after initial treatment.My breast tumor is at least 1 cm large, and I don't have cancer only in my underarm lymph nodes.You have enough infection-fighting white blood cells in your body.Your platelet count is 100,000 or higher.
- Group 1: Arm III (TL)
- Group 2: Arm I (THL)
- Group 3: Arm II (TH)
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
For what purpose is Trastuzumab most commonly prescribed?
"Trastuzumab is most often used to treat patients with metastatic bladder cancer. However, it can also help patients with inflammatory breast cancer (ibc), acquired immunodeficiency syndrome, and advanced thymoma."
Are investigators looking for more test subjects?
"Unfortunately, this particular clinical trial is not looking for patients at the moment. It was originally posted on December 1st, 2008 but was edited most recently on September 23rd, 2022. Although this study is closed to new patients, there are 3395 other trials that are still open and recruiting."
Is Trastuzumab a treatment with a lot of adverse side effects?
"There is some data to support Trastuzumab's efficacy, and this medication has been through multiple rounds of testing to confirm its safety. Therefore, it received a score of 3."
To what other research has Trastuzumab been tied?
"As of now, there are 1038 ongoing clinical trials observing the effects of Trastuzumab. Out of these, 273 are in Phase 3. Though several studies for Trastuzumab are based in Seattle, 54854 locations are running trials for Trastuzumab."
Share this study with friends
Copy Link
Messenger